A Study to Evaluate Seladelpar in Subjects With Nonalcoholic Steatohepatitis (NASH)
Stopped early · Phase 2 · Has a placebo group
Conditions studied: NASH - Nonalcoholic Steatohepatitis
In brief
A Phase 2, Double-Blind (DB), Randomized, Placebo-Controlled Study Followed by an Open-Label Extension Period to Evaluate the Activity of Seladelpar in Subjects with Nonalcoholic Steatohepatitis (NASH) OLE phase was not analyzed due to the early termination of the study
Key facts
- Study ID
- NCT03551522
- Run by
- Gilead Sciences
- People needed
- 181
- Starts
- 2018-04-30
- Expected to finish
- 2020-08-10
- Last updated by the study team
- 2022-09-15
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
Where it is running
- CymaBay Research Site — Glendale, Arizona, United States
- CymaBay Research Site — Tucson, Arizona, United States
- CymaBay Research Site — Los Angeles, California, United States
- CymaBay Research Site — Boca Raton, Florida, United States
- CymaBay Research Site — Lakewood Rch, Florida, United States
- CymaBay Research Site — Flowood, Mississippi, United States
- CymaBay Research Site — Clarksville, Tennessee, United States
- CymaBay Research Site — Germantown, Tennessee, United States
- CymaBay Research Site — Hermitage, Tennessee, United States
- CymaBay Research Site — Knoxville, Tennessee, United States
- CymaBay Research Site — Chandler, Texas, United States
- CymaBay Research Site — Dallas, Texas, United States
- CymaBay Research Site — Live Oak, Texas, United States
- CymaBay Research Site — Rollingwood, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.